Pulmonology

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

The new therapy, marketed as Jascayd, previously demonstrated safety and efficacy in the phase 3 FIBRONEER-IPF trial.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

INO-3107 immunotherapy significantly reduces surgeries for recurrent respiratory papillomatosis.

Q3 2025 saw more research emerge in asthma therapeutics and management as well as rarer pulmonary diseases.

September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

A meta-analysis confirmed CARATkids as a reliable tool for assessing asthma and allergic rhinitis control in children aged 6–12 years.

Cytisinicline shows promise as a safe and effective smoking cessation treatment, significantly improving quit rates in COPD.

AstraZeneca's Airsupra gains FDA approval for mild asthma, expanding its current label.

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.

Baseline emphysema detected in low-dose CT scans predicts long-term mortality in asymptomatic adults.

A study links paternal prepubertal passive smoke exposure to impaired lung function in offspring.

August 2025 saw a number of novel approvals and expert perspectives for World Lung Cancer Day.

The TETON-2 study met its primary endpoint, significantly improveing lung function in IPF.

Combining salivary bacteria, serum markers, and past attack history improves risk prediction for severe asthma attacks in children.

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

In this video, the last in a 5-part series, panelists discuss their future outlook on bronchiectasis management.

In this video, the fourth in a 5-part series, panelists discuss who may benefit from brensocatib's approval.

In this video, the third in a 5-part series, panelists discuss data from the phase 3 ASPEN trial.

In this video, the second in a 5-part series, panelists discuss the recent FDA approval of brensocatib.